Regeneron Pharmaceuticals Non-GAAP EPS of $9.77 beats by $1.02, revenue of $2.86B beats by $60M
Regeneron Pharmaceuticals press release  (NASDAQ:REGN): Q2  Non-GAAP EPS of $9.77  beats by $1.02.
Revenue of $2.86B (-44.4% Y/Y)  beats by $60M.
EYLEAÂ U.S.Â net sales increased 14% Y/Y to $1.62B.
DupixentÂ global net salesÂ increased 40% Y/Y to $2.09B.
FDA approved Dupixent for atopic dermatitis in children aged 6 months to 5 years and eosinophilic esophagitis in adults and adolescents; FDA priority review granted for prurigo nodularis.
FY2022, the company now expects adjusted gross margin on net product sales of 92% to 93% raised from prior outlook of 90% to 92%.